Loading...
•
Dec 31, 2021
Relmada Q4 2021 Earnings Report
Relmada reported preliminary and unaudited financial results.
Key Takeaways
Relmada Therapeutics reported its Q4 and full year 2021 financial results, highlighting the completion of two human abuse potential studies confirming no meaningful abuse potential of REL-1017 and anticipating multiple key data readouts throughout the remainder of the year.
Completed two human abuse potential (HAP) studies which confirmed no meaningful abuse potential of REL-1017 compared to oxycodone and ketamine.
Anticipate multiple key data readouts throughout the remainder of the year.
Expect data from RELIANCE III in mid-2022.
Data in the third and fourth quarters from RELIANCE I and RELIANCE II.
Relmada
Relmada
Forward Guidance
Relmada anticipates multiple key data readouts throughout the remainder of the year, as the multiple ongoing clinical studies that comprise RELIANCE continue to progress.
Positive Outlook
- Expect data from RELIANCE III in mid-2022
- Data in the third quarter from RELIANCE I
- Data in the fourth quarter from RELIANCE II
- REL-1017 has no meaningful abuse potential
- Strong balance sheet